Clinical trial / 2017
Resveratrol supplementation did not consistently improve walking performance in older adults with peripheral artery disease.
The RESTORE trial randomized 66 patients aged 65 or older with peripheral artery disease to 125 mg/d resveratrol, 500 mg/d resveratrol, or placebo for 6 months. Six-month mean (SE) changes in 6-minute walk distance were 4.6 (8.1) m for the 125-mg group, -12.8 (7.5) m for the 500-mg group, and -12.3 (7.9) m for the placebo group (P = .07 for 125 mg vs placebo; P = .96 for 500 mg vs placebo). Changes in maximal treadmill walking time were 0.5 (2.3) minutes for 125 mg, -0.6 (2.1) minutes for 500 mg, and 0.4 (2.1) minutes for placebo (P = .18 and P = .12 vs placebo, respectively). The authors concluded there was no consistent evidence that resveratrol improves walking performance in this population.
- Study type
- Double-blind, parallel-design randomized clinical trial
- Who was studied
- 66 participants aged 65 years or older with peripheral artery disease
- What was measured
- Change in 6-minute walk distance at 6-month follow-up; maximal treadmill walking time
THE PAPER
Effect of Resveratrol on Walking Performance in Older People With Peripheral Artery Disease: The RESTORE Randomized Clinical Trial.
McDermott MM, Leeuwenburgh C, Guralnik JM, Tian L, Sufit R, Zhao L, Criqui MH, Kibbe MR, Stein JH, Lloyd-Jones D, Anton SD, Polonsky TS, Gao Y, de Cabo R, Ferrucci L. JAMA Cardiol, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.